Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group.

Fatma Gül Demirkan Kadir Ulu Kübra Oztürk Serife Gül Karadag Semanur Ozdel Hafize Emine Sönmez Figen Cakmak Ferhat Demir Betul Sozeri Nuray Aktay Ayaz

Published in: Expert opinion on biological therapy (2021)

ABP 501 has a gradual increase in prescription in pediatric rheumatology. Real-life data of the cohort announce that ADL biosimilar is a suitable and effective treatment option for patients with JIA in case of indication.

Keyphrases

juvenile idiopathic arthritis
rheumatoid arthritis
electronic health record
big data
artificial intelligence
combination therapy
deep learning